BPTS
- Biophytis S.A.
()
Overview
Company Summary
Biophytis S.A., commonly known as Biophytis, is a clinical-stage biotechnology company that focuses on developing novel drug candidates for the treatment of age-related diseases. The company primarily aims to address the unmet medical needs of elderly patients suffering from debilitating age-related conditions.
Utilizing its expertise in biology, aging mechanisms, and therapeutic interventions, Biophytis is committed to developing innovative therapeutics to enhance healthy aging and provide better quality of life to patients. The company's pipeline involves the development of drug candidates targeting age-related diseases across various organs and systems, including skeletal muscle, eye, and central nervous system.
One of Biophytis' key programs is the development of Sarconeos, an orally administered small molecule designed to treat sarcopenia, a condition characterized by the loss of muscle mass and strength that commonly affects the elderly population. Sarconeos aims to improve muscle function, enhance mobility, and restore independence in sarcopenia patients.
In addition to its focus on sarcopenia, Biophytis also has ongoing programs targeting age-related vision disorders, such as dry age-related macular degeneration (AMD) and retinitis pigmentosa. The company's investigational drug, Macuneos, aims to slow the progression of vision loss and preserve visual function in these conditions.
Biophytis collaborates with academic institutions, research organizations, and pharmaceutical companies to leverage their expertise, technology, and resources in advancing its drug development programs. The company also conducts clinical trials to assess the safety, efficacy, and tolerability of its drug candidates, with the ultimate goal of obtaining regulatory approvals and bringing novel treatments to market.
Overall, Biophytis is dedicated to improving the health and well-being of aging individuals by developing innovative therapeutic interventions for age-related diseases, addressing the significant unmet medical needs in this patient population.